A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 2

Conditions

Advanced Cancer

Treatments

Drug: vorinostat

Study type

Interventional

Funder types

Industry

Identifiers

NCT00907738

0683-007

2009_595

Details and patient eligibility

About

This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.

Enrollment

27 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient participated in one of the five vorinostat base protocols, has not shown tumor progression on that study, and has tolerated the study drug
Patient did not withdraw from the base protocol
Patient agrees to practice effective birth control during the study

Exclusion criteria

Patient is receiving other standard and/or investigational anticancer therapy
Patient has any condition or disease that would interfere with compliance or pose addition risk in administering the study drug